BackgroundRecently, ctDNA has become the focus for scientists with respect to personalized treatment, early screening, precise diagnosis, and prognosis of BC. This paper aims to use bibliometric analysis to investigate the research status and future trends in this field.MethodsAll the related literature in the field of ctDNA and breast cancer was gathered from the Web of Science Core Collection. Data analyses were performed with R package Bibliometrics, VOS viewer 1.6.18, and online analysis in WoS. IBM SPSS (version 26.0) was used for statistical analysis.ResultsA total of 739 publications, including 472 articles and 267 reviews, were retrieved. The overall number of articles published showed an upward trend. The United States has the larg...
BackgroundMetastatic breast cancer (mBC) is a heterogenous disease with increasing availability of t...
Noninvasive circulating tumor DNA (ctDNA) can be used to predict breast cancer recurrence and progno...
© 2020 Andjelija ZivanovicPhenotypic diversity of breast cancers poses insurmountable challenges in ...
BackgroundRecently, ctDNA has become the focus for scientists with respect to personalized treatment...
Breast cancer is currently classified by immunohistochemistry. However, technological advances in th...
With the incidence of breast cancer steadily rising, it is important to explore novel technologies t...
Background: With rapid development in molecular biology techniques and a greater understanding of ca...
Precision Medicine is becoming the new paradigm in healthcare as it enables better resources allocat...
Introduction Breast cancer is the most prevalent cancer and the second leading cause of cancer death...
Metastatic breast cancer is usually diagnosed after becoming symptomatic, at which point it is rarel...
The availability of blood-based markers topredict response of a solid tumor to treatment, estimate p...
Breast cancer is clinically and biologically heterogeneous and is classified into different subtypes...
Circulating tumour DNA (ctDNA) analysis shows great potential both as an approach to understand the ...
Liquid biopsy-based biomarkers, including circulating tumor cells (CTCs) and circulating tumor DNA (...
PURPOSECirculating tumor DNA (ctDNA) detection is a minimally invasive technique that offers dynamic...
BackgroundMetastatic breast cancer (mBC) is a heterogenous disease with increasing availability of t...
Noninvasive circulating tumor DNA (ctDNA) can be used to predict breast cancer recurrence and progno...
© 2020 Andjelija ZivanovicPhenotypic diversity of breast cancers poses insurmountable challenges in ...
BackgroundRecently, ctDNA has become the focus for scientists with respect to personalized treatment...
Breast cancer is currently classified by immunohistochemistry. However, technological advances in th...
With the incidence of breast cancer steadily rising, it is important to explore novel technologies t...
Background: With rapid development in molecular biology techniques and a greater understanding of ca...
Precision Medicine is becoming the new paradigm in healthcare as it enables better resources allocat...
Introduction Breast cancer is the most prevalent cancer and the second leading cause of cancer death...
Metastatic breast cancer is usually diagnosed after becoming symptomatic, at which point it is rarel...
The availability of blood-based markers topredict response of a solid tumor to treatment, estimate p...
Breast cancer is clinically and biologically heterogeneous and is classified into different subtypes...
Circulating tumour DNA (ctDNA) analysis shows great potential both as an approach to understand the ...
Liquid biopsy-based biomarkers, including circulating tumor cells (CTCs) and circulating tumor DNA (...
PURPOSECirculating tumor DNA (ctDNA) detection is a minimally invasive technique that offers dynamic...
BackgroundMetastatic breast cancer (mBC) is a heterogenous disease with increasing availability of t...
Noninvasive circulating tumor DNA (ctDNA) can be used to predict breast cancer recurrence and progno...
© 2020 Andjelija ZivanovicPhenotypic diversity of breast cancers poses insurmountable challenges in ...